New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:49 EDTCIEN, OVTI, SWY, ARNA, SPLKOptions with decreasing implied volatility: OVTI SPLK SWY CIEN ARNA
News For OVTI;SPLK;SWY;CIEN;ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:04 EDTSPLKSplunk volatility elevated into Q1 and outlook
Subscribe for More Information
May 20, 2015
10:00 EDTSPLKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:16 EDTSPLKSplunk Q1 revenue likely to beat expectations, says Oppenheimer
Subscribe for More Information
07:09 EDTSPLKSplunk upgraded to Outperform from Neutral at Macquarie
Macquarie upgraded Splunk to Outperform with a $87 price target based on efforts to expand new customer adoption and the application layer. The firm said Splunk has provided increased flexibility in the product evaluation phase, which should improve new customer adoption, and extended efforts to build full solutions in the application layer. Macquarie also believes Splunk could emerge as a winner in Big Data analytics, resulting in new customer wins.
May 18, 2015
12:00 EDTSPLKSplunk selloff following CTO change unwarranted, says Cantor
Subscribe for More Information
09:02 EDTOVTIOmniVision and Silicon Line GmbH announce collaboration
Subscribe for More Information
08:07 EDTSPLKSplunk appoints Snehal Antani as Chief Technology Officer
Subscribe for More Information
May 11, 2015
19:15 EDTARNAOn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTARNAArena Pharmaceuticals reports Q1 EPS (10c), consensus (14c)
Subscribe for More Information
16:22 EDTARNAArena Pharmaceuticals enters collaboration with Roivant Sciences
Arena Pharmaceuticals announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin. Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and neuropsychiatric disturbances, including psychoses, in patients with dementia and other neurological diseases. In addition, Roivant may pursue the development of nelotanserin for other neuropsychiatric disorders. Roivant will be responsible for funding the development and commercialization of nelotanserin. Under the agreement, Arena will manufacture clinical supply and commercial product to sell to Roivant. Arena will receive a $4.0M upfront payment and is eligible to receive $41.5M in regulatory and development milestone payments. Arena is also eligible to receive 15% of net sales of nelotanserin in exchange for the manufacture and supply of finished commercial drug product, and up to a total of $60.0M in one-time purchase price adjustment payments tied to certain commercial sales milestones.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use